Reversal of defective peripheral nerve conduction velocity, nutritive endoneurial blood flow, and oxygenation by a novel aldose reductase inhibitor, WAY-121,509, in streptozotocin-induced diabetic rats

Journal of Diabetes and its Complications

Volumn 10, Issue 1, 1996, Pages 43-53

  Cameron, Norman E ^a   Cotter, Mary A ^a   Dines, Kevin C ^a   Hohman, Thomas C ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; FRUCTOSE; INOSITOL; MINALRESTAT; POLYOL; SORBITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS SHUNT; ARTICLE; BLOOD FLOW; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFECT; ENDONEURIUM; GLUCOSE BLOOD LEVEL; HYDROGEN CLEARANCE; MALE; MICROELECTRODE; MOTOR NERVE CONDUCTION; NERVE CONDUCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; OXYGEN TENSION; OXYGENATION; PERIPHERAL NERVE; PRIORITY JOURNAL; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES;

ALDEHYDE REDUCTASE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; FRUCTOSE; INOSITOL; MALE; NEURAL CONDUCTION; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; SCIATIC NERVE; SORBITOL;

EID: 0030063732     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(94)00076-X     Document Type: Article

References (60)

1. Dvornik D: Hyperglycemia in the pathogenesis of diabetic complications, in Porte D (ed.), Aldose Reductase Inhibition: An Approach to the Prevention of Diabetic Complications. New York, McGraw-Hill, 1987, pp. 69-151.
2. Sarges R, Oates PJ: Aldose reductase inhibitors: Recent developments. Prog Drug Res 40:99-161, 1993.
3. Boulton AJM, Levin S, Comstock J: A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 33: 431-437, 1990.
4. Santiago JV, Sönksen PH, Boulton AJM, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B and the Tolrestat Study Group: Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: Effects on nerve function. J Diabet Complications 7:170-178, 1993.
5. Sima AAF, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B and the Tolrestat Study Group: Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J Diabet Complications 7: 157-169, 1993.
6. Cameron NE, Cotter MA, Robertson S: The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats. Q J Exp Physiol 74:917-926, 1989.
7. Cameron NE, Leonard MB, Ross I, Whiting P: The effects of Sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin diabetic rat. Diabetologia 29:168-174, 1986.
8. Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, Ohkubo Y, Notsu, Yamaguchi I: Characterisation of a novel aldose reductase inhibitor, FR74366, and its effect upon diabetic cataract and neuropathy in the rat. Metabolism 40:77-87, 1991.
9. Cameron NE, Cotter MA: Dissociation between biochemical and functional effects of the aldose reductase inhibitor ponalrestat on peripheral nerve in diabetic rats. Br J Pharmacol 107:939-944, 1992.
10. Cameron NE, Cotter MA, Dines KC, Maxfield EK, Carey F, Mirrlees DJ: Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 37:651-663, 1994.
11. Greene DA, Lattimer SA, Sima AAF: Pathogenesis and prevention of diabetic neuropathy. Diab Metab Rev 4:201-221, 1988.
12. Sredy J, Flam BR, Sawicki DR: Adenosine triphosphatase activity in sciatic nerve tissue of streptozotocin-induced diabetic rats with and without high dietary sucrose: Effects of aldose reductase inhibitors. Proc Soc Exp Biol Med 197:135-142, 1991.
13. Hotta N, Kakuta H, Fukasawa H, Koh N, Sakakibara F, Komori H, Sakamoto N: Effect of niceritrol on streptozotocin-induced diabetic neuropathy in rats. Diabetes 41:587-591, 1992.
14. Cameron NE, Cotter MA: Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: Evidence from experimental studies. Diabetic Med 10:593-605, 1993.
15. Cameron NE, Cotter MA, Low PA: Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits. Am J Physiol 261:E1-E8, 1991.
16. Maxfield EK, Cameron NE, Cotter MA, Dines KC: Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats. Diabetologia 36:1230-1237, 1993.
17. 2+ antagonist, nimodipine, on existing diabetic neuropathy in the BB/Wor rat. Br J Pharmacol 111:887-893, 1994.
18. Tuck RR, Schmelzer JD, Low PA: Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107:935-950, 1984.
19. Cameron NE, Cotter MA: Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: Role of polyol pathway activity. Diabetologia 35:1011-1019, 1992.
20. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA: Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 21:205-211, 1993.
21. 1 analogue TFC 612 on diabetic neuropathy in streptozotocin-induced diabetic rats: Comparison with aldose reductase inhibitor ONO 2235. Diabetes 38:832-838, 1989.
22. Calcutt NA, Mizisin AP, Kalichman MW: Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve. Eur J Pharmacol 251:27-33, 1994.
23. Hotta N, Kakuta H, Koh N, Sakakibara F, Komori H, Inukai S, Naito S, Sakamoto N: Effect of a new potent aldose reductase inhibitor, "TAT" on diabetic neuropathy of rats [Abstract]. Diabetologia 35(suppl 1):A151, 1992.
24. Stevens EJ, Carrington AL, Tomlinson DR: Nerve ischaemia in experimental diabetes [Abstract]. Diabetologia 36(suppl 1):A57, 1993.
25. Karasu C, Dewhurst M, Stevens EJ, Tomlinson DR: Effects of aldose reductase inhibitor or anti-oxidant treatments on sciatic nerve laser Doppler flux in experimental diabetes [Abstract]. J Physiol 475P:69P, 1994.
26. Low PA, Lagerlund TD, McManis PG: Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy. Int Rev Neurobiol 31:355-438, 1989.
27. Kihara M, Zollman PJ, Smithson IL, Lagerlund TD, Low PA: Hypoxic effect of exogenous insulin on normal and diabetic peripheral nerve. Am J Physiol 266:E980-E985, 1994.
28. Malmas MS, Hohman TC, Millen J: Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1-3-diones: 2-[(4-bromo-2-fluorophenyl)-methyl]-6-fluorospiro-[isoquinoline-4(1H), 3′ pyrrolidine]-1,2′, 3,5′ (2H)-tetrone and congeners. J Med Chem 37:2043-2058, 1994.
29. 2 clearance curves used to measure blood flow in rat sciatic nerve. J Physiol 414:35-54, 1989.
30. Newrick PG, Wilson AJ, Jakubowski J, Boulton AJM, Ward JD: Sural nerve oxygen tension in diabetes. BMJ 293:1053-1054, 1986.
31. Guerrant GO, Moss CW: Determination of monosaccharides as aldonitrile O-methyloxamine, alditol and cyclitol acetate derivatives by gas chromatography. Anal Chem 56:633-638, 1984.
32. Powell HC, Garrett RS, Kador PF, Mizisin AP: Fine-structural localization of aldose reductase and ouabain-sensitive, K(+)-dependent p-nitro-phenylphosphatase in rat peripheral nerve. Act a Neuropathol (Berl) 81:529-539, 1991.
33. Zochodne DW, Ho LT: Hyperemia of injured peripheral nerve: Sensitivity to CGRP antagonism. Brain Res 598:59-66, 1992.
34. Hohman TC, Carper D: Hypertonic stress induces aldose reductase and myo-inositol accumulation in lens epithelial, kidney endothelial and Chinese hamster ovary cells, in Sakimoto N, Kinoshita JH, Kador PF, Hotta N (eds), Current Concepts of Aldose Reductase and its Inhibitions. Amsterdam, Elsevier, 1990, pp. 31-41.
35. Cameron NE, Cotter MA, Robertson S: Angiotensin converting enzyme inhibition prevents the development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 35:12-18, 1992.
36. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK: Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 37:449-459, 1994.
37. Tesfaye S, Harris N, Jakubowski JJ, Mody C, Wilson RM, Rennie IG, Ward JD: Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: A novel technique of nerve photography and fluorescein angiography. Diabetologia 36:1266-1274, 1993.
38. Simpson LO: Altered blood rheology in the pathogenesis of diabetic and other neuropathies. Muscle Nerve 11: 725-744, 1988.
39. Rillaerts EG, Vertommen JJ, De Leeuw IH: Effects of statil (ICI 128436) on erythrocyte viscosity in vitro. Diabetes 37:471-475, 1988.
40. Bareford D, Jennings PE, Stone PCW, Baar S, Barnett AH, Stuart J: Effects of hyperglycaemia and sorbitol accumulation on erythrocyte deformability in diabetes mellitus. J Clin Pathol 39:722-727, 1986.
41. Robey C, Dasmahapatra A, Cohen MP, Suarez S: Sorbinil partially prevents decreased erythrocyte deformability in experimental diabetes mellitus. Diabetes 36: 1010-1013, 1987.
42. Bell MA, Weddell AGM: A descriptive study of the blood vessels of the sciatic nerve in the rat, man and other mammals. Brain 107:871-898, 1984.
43. Young MJ, Veves A, Walker MG, Boulton AJM: Correlations between nerve function and tissue oxygenation in diabetic patients: Further clues to the aetiology of diabetic neuropathy? Diabetologia 35:1146-1150, 1992.
44. Low PA, Schmelzer JD, Ward KK, Yao JK: Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy. Am J Physiol 250:E94-E99, 1986.
45. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, Van Den Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813, 1993.
46. Moncada S, Palmer RJM, Higgs EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43:109-142, 1991.
47. Gonzalez A-M, Sochor M, Hothersall JS, Mclean P: Effect of aldose reductase inhibitor (sorbinil) on integration of polyol pathway, pentose phosphate pathway, and glycolytic route in diabetic rat lens. Diabetes 33:196-199, 1986.
48. Beckman JS, Beckman TW, Chen J, Marshall P, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624, 1990.
49. Kashiwagi A, Kikkawa R: Abnormal glutathione redox cycle in cultured human endothelial cells for the pathogenesis of diabetic vascular complication, in Rifkin H, Colwell JA, Taylor SI (eds), Diabetes 1991. New York, Excerpta Medica, Elsevier, 1991, pp. 679-682.
50. Fondelli C, Signorini AM, Borgogni L, Gragnoli G: Tolrestat and superoxide anion production in type 2 diabetic patients [Abstract]. Diabetologia 36(suppl 1):A204, 1993.
51. Cameron NE, Cotter MA, Maxfield EK: Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 36:299-304, 1993.
52. Cotter MA, Cameron NE: Nitrovasodilator treatment improves sciatic nerve blood flow and attenuates the development of conduction velocity deficits in diabetic rats [Abstract]. Eur J Clin Invest 24(suppl 2):A48, 1994.
53. 2) synthesis by aortic rings from rats with streptozotocin-induced diabetes. Prostaglandins Leukot Essent Fatty Acids 44:233-236, 1991.
54. Ward KK, Low PA, Schmelzer JD, Zochodne DW: Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats. Brain 112:197-208, 1989.
55. Cotter MA, Dines KC, Cameron NE: Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost. Naunyn Schmiedebergs Arch Pharmacol 347:534-540, 1993.
56. Horrobin DF: The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 31:181-197, 1988.
57. Cotter MA, Dines KC, Cameron NE: Comparison of the effects of evening primrose oil and the putative active triglyceride, di-linolein mono-γ-linolenate (DLMG), on sciatic nerve conduction velocity in diabetic rats: Dose-response relationship and modulation of endoneurial blood flow [Abstract]. Diabetic Med 10(suppl 3):P67, 1993.
58. Cameron NE, Cotter MA, Dines KC, Maxfield EK: Pharmacological manipulation of vascular endothelium in non-diabetic and streptozotocin-diabetic rats: Effects on nerve conduction, hypoxic resistance and endoneurial capillarization. Diabetologia 36:516-522, 1993.
59. Kamata K, Miyata N, Kasuya Y: Functional changes in potassium channels in aortas from rats with streptozotocin-induced diabetes. Eur J Pharmacol 166:319-323, 1989.
60. Langenstroer P, Pieper GM: Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol 263:H257-H265, 1992.